J&J Drops Alligator’s MAb ADC-1013 After Reviewing Combination Data

01 Aug 2019

The anti-CD40 antibody underperformed in some preclinical cancer combination studies, leading J&J to prioritize other assets. Alligator Bioscience will now advance ADC-1013 while seeking a new partner.

Returned — Janssen had gained exclusive rights for ADC-1013 in 2015 • Source: Shutterstock

J&J Drops Alligator’s MAb ADC-1013 After Reviewing Combination Data

More from Business

More from Scrip